Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04529161
Other study ID # UniterFMD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date October 30, 2022

Study information

Verified date March 2024
Source Uniter Onlus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Literature experiences demonstrated the impact of medically-assisted pulsed fasting on olfactory behavior in both the animal and human models and - conversely - the lack of homogeneous results linked - up to now - to administrations of pulsed fasting which are not widely codified. Thus, objective of this study protocol is to evaluate the olfactory-gustatory aspects and blood patterns of a group of subjects suffering from obesity / overweight after a 6-month period of Fasting Mimicking Diet (FMD) (Group A) - consisting of a caloric restriction regimen - compared to a group of homogeneous subjects observing their own eating habits (Group B) which - according to a "cross-over" model - will undergo FMD in the following semester during which the subjects belonging to Group A will observe their eating habits.


Description:

A group of obese and/or overweighted patients who did not pass screening criteria (BMI andor neuropsychological testing) to undergo surgical procedure aimed at reducing weight (grastrectomy, bypass, other…) will follow a 6-month period of FMD followed by 6-month period of routinary eating behaviour (Group A) or viceversa (Group B). All the patients will undergo - before and after the administration of FMD or the routinary diet habit - a battery of: - Olfactory test (sniffin' stick test) - Taste Test (Taste strips) - Blood Samples including: IGF-1, IGFBP1/3, VEGF, insulin, adiponectin, c reactive protein, plasma ghrelin, serum glucose, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), total cholesterol, triglycerides (TGs), high density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol, erythrocyte sedimentation rate (ESR), conjugated and unconjugated bilirubin, uraemia, serum creatinine and leptin. - anthropometeric measures, including height and body weight, BMI, waist circumference (WC), estimation of fat mass (FM, in % and Kg), skeletal muscle mass (MM, in % and Kg) and grade of visceral fat (VF level)


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date October 30, 2022
Est. primary completion date October 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - subjects excluded from bariatric surgical treatment for failing to neuropsychological tests or for co-morbidities that would excessively increase the intra-operative and/or - non-responders to any previous dietary / nutritional treatment - BMI > 25 Exclusion Criteria: - Subjects under the age of 18 and over 75 years. - Subjects already undergoing bariatric surgical treatment - Women who are pregnant or breastfeeding - Hormonal therapies and / or chemotherapy in place - Active mental or psychiatric illness - Addiction to drugs of abuse or alcohol - other acute or chronic systemic disorders - Severe hypertension (systolic blood pressure> 200 mm Hg and / or diastolic blood pressure> 105 mm Hg) - Visual impairment (for completion of neuropsychological tests) - Inability to complete home FMD

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fasting Mimicking Diet (FMD)
The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
Routinary diet habits
Subjects will follow their routinary eating habits for 6 consecutive months

Locations

Country Name City State
Italy University of Rome Tor Vergata - UNITER Onlus Roma Rome

Sponsors (2)

Lead Sponsor Collaborator
Uniter Onlus University of Rome Tor Vergata

Country where clinical trial is conducted

Italy, 

References & Publications (10)

Cameron JD, Goldfield GS, Doucet E. Fasting for 24 h improves nasal chemosensory performance and food palatability in a related manner. Appetite. 2012 Jun;58(3):978-81. doi: 10.1016/j.appet.2012.02.050. Epub 2012 Mar 2. — View Citation

English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002 Jun;87(6):2984. doi: 10.1210/jcem.87.6.8738. — View Citation

Goldstone AP, Prechtl CG, Scholtz S, Miras AD, Chhina N, Durighel G, Deliran SS, Beckmann C, Ghatei MA, Ashby DR, Waldman AD, Gaylinn BD, Thorner MO, Frost GS, Bloom SR, Bell JD. Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food. Am J Clin Nutr. 2014 Jun;99(6):1319-30. doi: 10.3945/ajcn.113.075291. Epub 2014 Apr 23. — View Citation

Meyer-Gerspach AC, Wolnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, Steinert RE, Beglinger C. Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav. 2014 Apr 22;129:265-71. doi: 10.1016/j.physbeh.2014.02.043. Epub 2014 Feb 28. — View Citation

Pager J, Giachetti I, Holley A, Le Magnen J. A selective control of olfactory bulb electrical activity in relation to food deprivation and satiety in rats. Physiol Behav. 1972 Oct;9(4):573-9. doi: 10.1016/0031-9384(72)90014-5. No abstract available. — View Citation

Palouzier-Paulignan B, Lacroix MC, Aime P, Baly C, Caillol M, Congar P, Julliard AK, Tucker K, Fadool DA. Olfaction under metabolic influences. Chem Senses. 2012 Nov;37(9):769-97. doi: 10.1093/chemse/bjs059. Epub 2012 Jul 25. — View Citation

Stafford LD, Welbeck K. High hunger state increases olfactory sensitivity to neutral but not food odors. Chem Senses. 2011 Jan;36(2):189-98. doi: 10.1093/chemse/bjq114. Epub 2010 Oct 26. — View Citation

Tong J, Mannea E, Aime P, Pfluger PT, Yi CX, Castaneda TR, Davis HW, Ren X, Pixley S, Benoit S, Julliard K, Woods SC, Horvath TL, Sleeman MM, D'Alessio D, Obici S, Frank R, Tschop MH. Ghrelin enhances olfactory sensitivity and exploratory sniffing in rodents and humans. J Neurosci. 2011 Apr 13;31(15):5841-6. doi: 10.1523/JNEUROSCI.5680-10.2011. — View Citation

Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001 Apr;50(4):707-9. doi: 10.2337/diabetes.50.4.707. — View Citation

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15;9(377):eaai8700. doi: 10.1126/scitranslmed.aai8700. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sniffing stick test change Quantitative screening of olfactory performance From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Primary Taste Strips Quantitative assessment of taste performance From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results serum glucose From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma growth factors: IGF-1 From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma growth factors: IGFBP1/3 From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma growth factors: insulin From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma growth factors: VEGF From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results plasma ghrelin. From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma inflammatory markers: adiponectin From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results Serum/plasma inflammatory markers: c reactive protein From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results alanine aminotransferase From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results aspartate aminotransferase From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results total cholesterol From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results triglycerides From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results high density lipoprotein cholesterol From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results low-density lipoprotein cholesterol From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results erythrocyte sedimentation rate From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results conjugated and unconjugated bilirubin From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results uraemia From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results serum creatinine From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary Incidence of abnormal laboratory tests results leptin From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures height From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures weight From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures body mass index From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures waist circumference From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures estimation of fat mass From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures estimation of skeletal muscle mass From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
Secondary anthropometric measures estimation of grade of visceral fat From date of randomization until the date of first documented progression, assessed at the 6th and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2